Now approved for TCAR
A new layer
of defense
The only MicroNet™ mesh-covered carotid stent, CGuard® Prime is the next generation of carotid stenting, featuring a unique dual-layer design to take stroke prevention to a new level.
Your trusted layer of defense against the significant risk of plaque prolapse and embolization
Stroke is the third leading cause of death globally1
Approximately 2/3 of major adverse events occurred after CAS procedures, likely caused by late emboli through the struts of the stent2
~67%
CGuard Prime Carotid Stent demonstrated low rates of major adverse events
0.95%
through 30 days3
Death, any Stroke, or MI† (DSMI)
The lowest independently adjudicated 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS). 3-12
1.93%
through 1 year
Composite of DSMI through 30 days or ipsilateral stroke 31-365 days post-index procedure. 3‡
Smart design for stroke prevention
Defense designed
by InspireMD
We're advancing carotid intervention with innovative designs that are reshaping industry standards for stroke prevention and neuroprotection.
Why InspireMD?
Latest News
Dual-layered, dual benefits
Expert experiences
Hear from leading physicians about the clinical and patient benefits of the CGuard Carotid Stent
Dr. Alberto Cremonesi
Chief of the Cardiovascular Department at Maria Cecilia Hospital
Cotignola, Italy
Dr. Antonio Moreno
Chief Medical Officer of Endovascular Intervention World MEDICA
Madrid, Spain
Dr. Roberto Chiappa
Vascular Surgeon, Sandro Pertini Hospital
Rome, Italy
The CGuard Prime TransCarotid Stent System, when used in conjunction with an embolic protection system specified in the labeling, is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria outlined below:
- Patients with neurological symptoms and ≥ 50% stenosis of the common or internal carotid artery by angiogram, or patients without neurological symptoms and ≥ 80% stenosis of the common or internal carotid artery by angiogram.
- Patients having a vessel with reference diameters between 6.4mm and 9.0mm at the target lesion.
- A carotid bifurcation location that is at least 5 cm above the clavicle, verified through duplex Doppler ultrasound, computer tomography (CT) angiography, or magnetic resonance (MR) angiography.
Compatible Embolic Protection Systems: ENROUTE™ Transcarotid Neuroprotection System.
ENROUTE™ is a registered trademark of Boston Scientific Corporation.
* Among commercially available carotid stents. Data on file.
** Defense is defined as the absence of restenosis
† Myocardial Infarction
‡ Based on modified intent-to-treat Kaplan-Meier analysis
References:
- World Health Organization Fact Sheet. Top 10 causes of death. 2024
- M. Bosiers, et al. Eur J Vasc Endovasc Surg 2007; 33(2):135-141. doi:10.1016/j.ejvs.2006.09.019.
- Metzger DC, et al. JACC. 2025 Dec;18(24):3087-3097. doi:10.1016/j.jcin.2025.09.027
- Yadav JS, et al. N Engl J Med. 2004 Oct;351(15):1493-1501. doi: 10.1056/ NEJMoa040127.
- Iyer SS, et al. J Am Coll Cardiol. 2008;51(4):427-434. doi:10.1016/j.jacc.2007.09.045
- Higashida R, et al. Stroke vol. 41,2 (2010): e102-9. doi: 10.1161/STROKEAHA.109.564161.
- Brott TG, et al. N Engl J Med. 2010 Jul;363(1):11-23. doi: 10.1056/NEJMoa0912321. Epub 2010 May 26.
- Matsumura JS, et al. J Vasc Surg. 2012 Apr;55(4):968-76. doi: 10.1016/j.jvs.2011.10.120.
- U.S. Food and Drug Administration SSED: Roadsaver/CASPER Carotid Stent System (PMA P210030). 2024. Nov 20
- Gray WA, et al. J Am Coll Cardiol Intv. 2025 Feb;18(3):367-76. doi: 10.1016/j.jcin.2024.10.031.
- Safian RD, et al. J Am Coll Cardiol. 2006 Jun;47(12):2384-89. doi: 10.1016/j.jacc.2005.12.076.
- Langhoff R, et al. Cardiovasc Intervent Radiol. 2025 Mar;Vol 48 427–37. doi: 10.1007/s00270-025-04003-z.
- Wissgott, C et. al. J Endovasc Ther. 2017 Feb;24(1):130-137. doi:10.1177/1526602816671134
- Mazurek A, et al. Eur Heart J. 2020;41(Suppl 2):ehaa946.2404. doi:10.1093/ehjci/ehaa946.2404
- Mazurek A, et al. J Cardiovasc Surg. 2023; 64(6):570-582. doi:10.23736/S0021-9509.24.12933-3
- Lyden, S, et al. J Vasc Surg. 2026; 05. doi:10.1016/j.jvs.2026.05.027
- Kashyap VS, et al. Stroke. 2020 Sep;51(9):2620-2629. doi:10.1161/STROKEAHA.120.030550
- U.S. Food and Drug Administration SSED: CGuard Prime Carotid Stent System (PMA P240029-S005) 2026.